Routine Blood Indicators Combined With Sleep Questionnaires for the Identification of Cognitive Impairment in Parkinson's Disease: A Cross-Sectional Study With a Leakage-Free Nested Modeling Framework.
Combining routine blood indicators and sleep questionnaires is cross-sectionally associated with prevalent cognitive impairment in Parkinson's disease and adds information beyond clinical variables alone, with the full logistic regression model achieving an AUC of 0.943 in the untouched test set.
Key Findings
Results
LASSO feature selection identified 10 predictors of cognitive impairment in Parkinson's disease from 20 candidate variables.
The 10 retained predictors were: education, disease duration, Hoehn-Yahr stage, platelet-to-lymphocyte ratio (PLR), monocyte-to-lymphocyte ratio (MLR), homocysteine, C-reactive protein (CRP), Pittsburgh Sleep Quality Index (PSQI), Epworth Sleepiness Scale (ESS), and REM Sleep Behavior Disorder Screening Questionnaire (RBDSQ).
Feature selection used L1-penalized logistic regression with the lambda.1se criterion, confined strictly to training data (70%, n=242) to prevent data leakage.
The cohort comprised 347 PD patients: 143 classified as PD-CI and 204 as PD-NCI based on MoCA < 26.
Results
The full logistic regression model achieved an AUC of 0.943 in the untouched test set, significantly higher than the baseline clinical model.
Full model AUC was 0.943 (95% CI: 0.896–0.990) in the held-out test set (n=105).
Baseline clinical model AUC was 0.844; the incremental gain over baseline was statistically significant (DeLong p=0.009).
Repeated 5×2 cross-validation yielded a more conservative AUC of 0.921 (SD=0.029).
Calibration was acceptable: slope 1.18, intercept 0.03, test Brier score 0.086 (95% CI 0.057–0.120).
Results
The baseline-plus-blood model and the full model showed comparable discriminative performance in the test set.
Baseline-plus-blood model AUC was 0.937 and baseline-plus-sleep model AUC was 0.889 in the test set.
The full model AUC (0.943) was comparable to baseline-plus-blood (0.937) but higher than baseline-plus-sleep (0.889) and baseline alone (0.844).
These comparisons were assessed using DeLong confidence intervals and between-model DeLong tests.
Results
Machine learning classifiers (random forest and gradient boosting) did not outperform logistic regression in discriminating cognitive impairment.
Random forest achieved an AUC of 0.956 and gradient boosting achieved 0.944 in the test set.
Neither RF nor GBM outperformed the full logistic regression model (AUC 0.943).
Four nested logistic regression models were constructed alongside these two machine learning classifiers for comparison.
Results
Model findings were stable across alternative MoCA cut-offs, supporting robustness of the outcome definition.
AUC ranged from 0.909 to 0.931 across alternative MoCA cut-offs.
Robustness was also examined with education-adjusted MoCA thresholds.
The primary outcome definition used MoCA < 26 to classify PD-CI.
Methods
The study employed a strictly leakage-free nested modeling framework to prevent data leakage during model development.
The cohort was divided into training (70%, n=242) and test (30%, n=105) sets by stratified sampling before any modeling steps.
All feature selection and hyperparameter tuning were confined to the training data; the test set was scored only once.
Generalization was additionally estimated by repeated 5×2 cross-validation.
This design is described as a key methodological safeguard against optimistic performance estimates.
Conclusions
The authors explicitly state that the model should be regarded as a candidate screening aid requiring external validation before any clinical use.
Limitations acknowledged include cross-sectional design, single-center recruitment, and only internal validation.
The authors call for 'external, preferably multicenter and prospective, validation before any clinical use.'
The study is described as quantifying 'the strength of association and the cross-sectional classification value' rather than establishing causal or predictive utility.
What This Means
This research suggests that a combination of routine blood test results and standardized sleep questionnaires can help identify cognitive impairment in people with Parkinson's disease with a high degree of accuracy. The study enrolled 347 Parkinson's patients and used a careful statistical approach to identify 10 key factors — including inflammatory blood markers (such as C-reactive protein, platelet-to-lymphocyte ratio, and homocysteine) and sleep-related measures (such as sleep quality, daytime sleepiness, and REM sleep behavior disorder screening) — that together were strongly associated with cognitive impairment. When all these factors were combined in a model and tested on a separate group of patients that had not been used in model development, the model correctly distinguished patients with and without cognitive impairment about 94% of the time, which was significantly better than using clinical information alone.
Importantly, the researchers used a rigorous 'leakage-free' methodology, meaning they were careful not to let the test data influence the model-building process — a common pitfall that can make models appear more accurate than they truly are. They also found that simpler statistical models performed just as well as more complex machine learning approaches like random forests and gradient boosting. The results were consistent when different thresholds for defining cognitive impairment were applied, suggesting the findings are robust.
However, this research suggests these results should be interpreted cautiously. The study was conducted at a single center, used a cross-sectional design (meaning data were collected at one point in time rather than followed over time), and was only validated internally. The authors emphasize that this model should be considered a candidate screening tool that needs to be tested in larger, multi-center, and prospective studies before it could be considered for actual clinical use. If validated externally, such a tool — relying only on blood tests and sleep questionnaires that are already routinely available — could offer a low-cost, accessible way to flag Parkinson's patients who may be at risk for cognitive impairment.
Check Your Own Numbers
Upload your bloodwork. We'll cross-reference your results against this study and 4,700 others.
Wang Z, Lam T, Zhang S, Song C, Pei X, Zhong J, et al.. (2026). Routine Blood Indicators Combined With Sleep Questionnaires for the Identification of Cognitive Impairment in Parkinson's Disease: A Cross-Sectional Study With a Leakage-Free Nested Modeling Framework.. Brain and behavior. https://doi.org/10.1002/brb3.71655